Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $42000.0.

  • Summit Therapeutics' Depreciation and Depletion rose 11000.0% to $42000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $126000.0, marking a year-over-year increase of 2989.69%. This contributed to the annual value of $89000.0 for FY2024, which is 5505.05% down from last year.
  • As of Q3 2025, Summit Therapeutics' Depreciation and Depletion stood at $42000.0, which was up 11000.0% from $37000.0 recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Depreciation and Depletion ranged from a high of $99000.0 in Q2 2022 and a low of $20000.0 during Q2 2024
  • Its 5-year average for Depreciation and Depletion is $56315.8, with a median of $46000.0 in 2023.
  • As far as peak fluctuations go, Summit Therapeutics' Depreciation and Depletion surged by 12571.43% in 2021, and later plummeted by 7000.0% in 2024.
  • Quarter analysis of 5 years shows Summit Therapeutics' Depreciation and Depletion stood at $79000.0 in 2021, then rose by 11.39% to $88000.0 in 2022, then tumbled by 65.91% to $30000.0 in 2023, then fell by 26.67% to $22000.0 in 2024, then skyrocketed by 90.91% to $42000.0 in 2025.
  • Its Depreciation and Depletion was $42000.0 in Q3 2025, compared to $37000.0 in Q2 2025 and $25000.0 in Q1 2025.